On July 16, Stryker fell 3.48% in after-hours trading, trading at $319.99 USD/share, with turnover of $26.14 million. The decline came amid broad after-hours weakness across the Healthcare Equipment sector, led by Intuitive Surgical's sharp 10.84% drop. Other peers also declined, including Boston Scientific down 0.83%, Medtronic down 0.34%, DexCom down 0.2%, and Abbott Laboratories down 0.13%.

The reversal was notable given that the sector had traded broadly higher during regular hours, with Abbott up 13.91% and Stryker itself gaining 3.71% intraday. The sector had already faced pressure earlier in the week when HCA Healthcare issued a disappointing business outlook on July 14, raising concerns about slowing healthcare demand. Goldman Sachs also cut its Stryker price target to $339 from $363, maintaining a Neutral rating. Stryker is scheduled to report Q2 results on July 30, with consensus EPS estimates at $3.46.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)